Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Hematology Analyzers, 2024

[one_third]

[/one_third]

[two_third_last]

[/two_third_last]

[wpdatatable id=106]

[one_third]

[/one_third]

[two_third_last]

Can labs bridge the hematology data disconnect?

October 2024—Do clinicians understand how the technology in hematology has evolved and how laboratory data can help guide their decisions? It’s a question roundtable participants took on when they met online Aug. 29 with CAP TODAY publisher Bob McGonnagle. “There’s a disconnect with our clinical colleagues,” said Olga Pozdnyakova, MD, PhD, of the Hospital of the University of Pennsylvania. She and others spoke about solutions, instruments, AI, and reference ranges—in addition to the staffing shortage. “It is first and foremost in our minds,” Maria (Ria) Vergara-Lluri, MD, of Keck School of Medicine of USC, said of the ongoing shortage.

Following their conversation below is an all-new CAP TODAY guide to hematology analyzers (pages 41–51). The questions we asked vendors about their instruments were updated and revised for the first time, providing new insight into the instruments on the market.

A few issues from our discussion in last year’s roundtable on hematology analyzers carry over to today’s conversation: the efforts to cut back on the number of manual differentials we’re asking to have done in labs; the continuing work around bands versus neutrophils; the remote viewing of cells, à la surgical pathology, when we want an automated look at blood cells; and artificial intelligence in the world of hematology. Fernando Chaves, is there something new here? Where do you place us in the state of hematology today?

Fernando Chaves, MD, director, medical and scientific affairs, specialty lab solutions, Siemens Healthineers: Our main focus continues to be on digitalization and digital integration to improve patient care and workflow. For manual reviews, it’s not a question of how many slides are needed but how much labor and turnaround time are required to review a slide. That’s why we focus on the importance of digital morphology, the ability to use digital hematology, which gives a full-field view on a computer screen and the same experience as you have on a microscope. You see not only random selected cells but also a view of the entire slide. You can see the context of each cell, navigate through the slide on the computer screen, and do it remotely. It saves time and shortens turnaround time.

Continue reading …
[/two_third_last]